Service Search

Mechanistic Toxicology and Risk Assessment Lipidomics Services

Q: How does lipidomics facilitate the construction of Adverse Outcome Pathways (AOPs)?

AOPs require a clear, causal link between a Molecular Initiating Event (MIE) and an apical adverse outcome (like reproductive organ failure). Lipidomics acts as the crucial biochemical bridge. By precisely quantifying membrane degradation, signaling shifts, or endocrine precursor depletion, we provide the absolute, quantifiable data needed to validate these mechanistic pathways for regulatory bodies like the EPA and OECD.

Q: What is the difference between adaptive lipid remodeling and a toxicological adverse event?

Biological systems adapt to minor stress by naturally adjusting their lipid composition (e.g., changing membrane saturation). However, a toxicological event triggers irreversible, destructive pathways. We differentiate the two by targeting specific, definitive damage markers—such as heavily oxidized polyunsaturated fatty acids or apoptotic ceramides—that are exclusively generated during actual toxicological injury.

Q: How do you quantify low-abundance inflammatory mediators like eicosanoids in complex liver tissues?

Liver tissues contain overwhelming amounts of triacylglycerols that severely suppress mass spectrometry signals. To quantify trace eicosanoids, we mandate multi-step Solid-Phase Extraction (SPE) enrichment to meticulously strip away the background fat. Combined with highly sensitive LC-MS/MS platforms running in MRM mode, we achieve reliable absolute quantification at pg/mL levels.

Q: Can untargeted lipidomics differentiate between the toxic mechanisms of structurally similar PFAS compounds?

Yes. While different PFAS chain lengths may cause similar phenotypic liver enlargement, their interactions with cellular receptors differ significantly. Untargeted lipidomics provides a holistic metabolic fingerprint. By applying principal component analysis (PCA) and multivariate statistics, we can identify the unique lipid cascades driven by specific PFAS analogs, highlighting subtle mechanistic differences.

Q: How does your platform ensure the stability of oxylipins and prevent ex vivo auto-oxidation?

Oxylipins and other ROS-sensitive lipids degrade rapidly once tissue is harvested. We strictly enforce sub-second liquid nitrogen flash-freezing protocols. During homogenization and extraction, we maintain cryogenic environments and utilize solvent systems pre-loaded with antioxidant shields, ensuring the detected oxidative stress genuinely reflects in vivo toxicity.

Q: Is spatial lipidomics (MALDI-MSI) applicable to whole-body sections of small ecotoxicology models like zebrafish?

Absolutely. MALDI-MSI is highly effective for small aquatic and mammalian models. We can section intact zebrafish, embryos, or bivalves and map the spatial distribution of specific lipids. This allows researchers to visually pinpoint exactly where a lipophilic toxicant bioaccumulates and simultaneously image the localized tissue damage occurring in that specific micro-environment.

Q: How do you handle the data integration of lipidomics with transcriptomics for mechanistic toxicology?

Modern toxicology relies on understanding how gene expression changes ultimately manifest in the metabolome. Through advanced network toxicology algorithms, we mathematically integrate quantitative lipidomic shifts directly with your RNA-Seq data. This direct correlation highlights the specific enzymatic nodes driving the observed toxic lipid phenotype.

Q: What is the sample volume requirement for evaluating endocrine-disrupting effects?

Thanks to the extreme sensitivity of our targeted lipidomics platforms, we require very low sample inputs. Typically, 50 microliters of serum/plasma or 10-30 milligrams of gonadal or liver tissue is completely sufficient to provide comprehensive, absolute quantification of cholesterol and its complex downstream endocrine steroid precursors.

Creative Proteomics provides high-resolution lipidomics to elucidate the molecular mechanisms of toxicity and support environmental risk assessments. We empower toxicologists to transition from phenotypic endpoints to molecular initiating events (MIEs) by delivering absolute quantification of lipidome shifts, oxidative stress, and endocrine disruption required for OECD Adverse Outcome Pathway (AOP) validation and regulatory safety evaluations.

Key capabilities

Endocrine Disruption Tracking: Quantify sterol flux and steroid precursors to validate the cross-generational reproductive toxicity of emerging pollutants.
Adverse Outcome Pathway (AOP) Validation: Link molecular lipid membrane degradation directly to apical endpoints like hepatotoxicity or neurodegeneration using gold-standard biomarkers.
Mixture Toxicology Deconvolution: Utilize advanced bioinformatics to isolate synergistic molecular targets from complex environmental co-exposures and pollutant cocktails.

Request Analysis

Submit Your Request Now

Our services have earned the trust of companies, schools, and organizations globally, and we remain dedicated to maintaining that trust.

Trends & Challenges
Integrated Solutions
Technical Advantages
Case Studies
FAQ

Lipidomic Profiling in Mechanistic Toxicology and Exposome Research

High-resolution LC-MS mechanistic toxicology lipidomics is now an indispensable analytical tool for bridging the gap between external chemical exposure and phenotypic toxicity.

Mechanistic Trends

In the era of Exposome research, regulatory bodies such as the EPA (through ToxCast) and international frameworks like the OECD AOP program are fundamentally shifting from traditional in vivo mortality assays toward mechanism-based, predictive risk assessments. High-impact toxicological research published in Nature and Cell Press emphasizes that the biological lipidome is one of the most sensitive and earliest responders to xenobiotic chemical stress. Toxicants such as per- and polyfluoroalkyl substances (PFAS), nanoplastics, and heavy metals rapidly induce lipid peroxidation, membrane remodeling, and lipotoxicity long before cellular apoptosis or tissue necrosis becomes histologically visible.

To build robust, regulatory-accepted evidence packages, toxicologists must precisely define Molecular Initiating Events (MIEs) and Key Events (KEs) at the biochemical level. High-resolution LC-MS mechanistic toxicology lipidomics is now an indispensable analytical tool for bridging the gap between external chemical exposure and phenotypic toxicity. By quantifying dynamic shifts in pro-inflammatory eicosanoids, apoptotic ceramides, and endocrine disruption lipids, researchers can establish irrefutable, data-driven evidence chains essential for modern environmental risk assessment lipidomics and safety pharmacology.

Critical Analytical Bottlenecks in Toxicity Mechanism Elucidation

Differentiating Adaptive Responses from Adverse Molecular Events. Biological models instinctively alter their lipid composition to maintain cellular homeostasis under sub-lethal stress. Distinguishing this benign adaptation from irreversible toxicological injury is difficult with untargeted profiling alone. Targeted absolute quantification of specific signals—like heavily oxidized phospholipids or an acute burst of apoptotic sphingolipids—is essential to confirm definitive toxicity.

Resolving Trace Lipid Mediators in Complex Matrices. Toxicological damage is often driven by low-abundance signaling lipids (e.g., oxylipins, prostaglandins). In complex in vivo models like liver or brain tissue, highly abundant structural lipids cause severe mass spectrometric ion suppression. Extracting and quantifying these trace inflammatory mediators against a massive lipid background remains a critical analytical challenge.

Deconvoluting Mixture Toxicity and Synergistic Interactions. Environmental exposures rarely involve isolated compounds. Evaluating synergistic or antagonistic effects of mixed pollutants severely complicates risk assessment. Traditional single-endpoint assays fail to untangle these multi-layered interactions, necessitating advanced multi-omics integration and network analysis to map how mixtures synergistically blockade metabolic checkpoints.

Situational Solution Matrix for Environmental Risk Assessment

Lipidomics provides a mechanistic bridge between chemical exposure and system-level toxicity. Select your specific exposure research scenario below to see the recommended workflow.

Endocrine Disrupting Chemicals (EDCs) and Reproductive Toxicity

Situation

Investigating reproductive toxicity triggered by endocrine disrupting chemicals such as bisphenols, phthalates, PFAS, or microplastics in zebrafish, rodent, or avian models.

Goal

Identify molecular evidence of endocrine disruption by quantifying sterol metabolism, cholesterol turnover, and steroid precursor depletion.

Recommended path

Bundle B (Targeted Validation) → Bioinformatic pathway interpretation

Recommended services

Sterol Lipids Targeted Lipidomics, Cholesterol Targeted Lipidomics, Targeted Lipidomics Service, Fatty Acid Oxidation and Its Metabolites Assay, Lipidomics Bioinformation Analysis

What you will get

Absolute molar quantification of cholesterol, sterol intermediates, and lipid hormone precursors, providing molecular evidence linking pollutant exposure to disrupted steroidogenesis pathways.

Hepatic Oxidative Stress and Hepatotoxicity Mechanism Mapping

Situation

Animal models exposed to industrial chemicals, pesticides, or PFAS display hepatomegaly, steatosis, or liver dysfunction.

Goal

Differentiate adaptive lipid accumulation from true oxidative damage, mitochondrial dysfunction, and inflammatory lipid signaling.

Recommended path

Bundle A (Discovery) → Bundle B (Targeted Validation)

Recommended services

Untargeted Lipidomics Profiling, Oxylipin Quantification and Pathway Profiling, Eicosanoid Analysis Service, Phospholipids Analysis Service, Targeted Lipidomics Service

What you will get

Quantitative evidence of lipid peroxidation, inflammatory eicosanoid bursts, and phospholipid degradation, enabling clear differentiation between metabolic adaptation and toxic injury.

Neurotoxicity and Blood-Brain Barrier Disruption

Situation

Investigating the neurotoxic effects of particulate matter, nanoparticles, pesticides, or microplastics on central nervous system integrity.

Goal

Identify lipid degradation associated with myelin damage, neuroinflammation, and apoptosis signaling.

Recommended path

Bundle A (Discovery) → Bundle B (Validation) → Bundle C (Spatial insight)

Recommended services

Untargeted Lipidomics Profiling, Sphingolipids Analysis Service, Ceramide Quantification Analysis, Phospholipids Analysis Service, MALDI-Imaging Lipidomics Services

What you will get

Mechanistic evidence of sphingomyelin degradation, ceramide accumulation, and spatial lipid distribution changes across brain regions affected by toxic exposure.

Building Adverse Outcome Pathways (AOPs) for Regulatory Submission

Situation

Generating mechanistic toxicology data packages required for regulatory frameworks such as EPA ToxCast, OECD AOP programs, or REACH chemical registration.

Goal

Link molecular initiating events (MIEs) to downstream metabolic and cellular damage through pathway-resolved lipidomics.

Recommended path

Bundle A (Discovery) → Bundle B (Validation) → Deep bioinformatic interpretation

Recommended services

Untargeted Lipidomics Profiling, Targeted Lipidomics Service, Oxylipin Quantification and Pathway Profiling, Fatty Acid Oxidation and Its Metabolites Assay, Lipidomics Bioinformation Analysis

What you will get

Mechanistic datasets linking exposure-driven lipid metabolism disruption with key toxicological pathways required for regulatory risk assessment documentation.

Spatially Resolved Tissue Toxicity and Pollutant Bioaccumulation

Situation

Persistent pollutants distribute unevenly across tissues, masking localized toxicity when samples are homogenized.

Goal

Visualize pollutant-induced lipid alterations directly within tissue architecture.

Recommended path

Bundle C (Spatial Lipidomics Insight)

Recommended services

MALDI-Imaging Lipidomics Services, Phospholipids Analysis Service, Sphingolipids Analysis Service, Glycerophospholipids Targeted Lipidomics, Ceramide Quantification Analysis

What you will get

High-resolution MALDI imaging maps demonstrating the spatial co-localization of pollutant accumulation with membrane lipid degradation and localized tissue damage.

Mixture Toxicity and Synergistic Pollutant Interactions

Situation

Environmental systems often involve co-exposure to multiple pollutants such as heavy metals, pesticide mixtures, or PFAS variants.

Goal

Identify metabolic checkpoints that collapse under combined exposure and distinguish synergistic toxicity mechanisms.

Recommended path

Bundle A (Discovery) → Bundle B (Validation) → Network toxicology modeling

Recommended services

Untargeted Lipidomics Profiling, Oxylipin Quantification and Pathway Profiling, Eicosanoid Analysis Service, Targeted Lipidomics Service, Lipidomics Bioinformation Analysis

What you will get

Network-level lipidomic datasets revealing synergistic pathway disruptions and metabolic nodes responsible for amplified toxicity in mixed-exposure environments.

Technical Advantages in Toxicity Risk Assessment

Creative Proteomics utilizes flagship-tier platforms, including the Sciex QTRAP® 6500+ and Thermo Orbitrap Exploris™ 480, to overcome the matrix interference challenges inherent in complex toxicological models.

Trace-Level Biomarker Sensitivity (pg/mL LLOQ)

Apoptotic signaling lipids and pro-inflammatory eicosanoids often exist at minute pg/mL concentrations. Our targeted LC-MS/MS platforms deliver the extreme dynamic range required to quantify these critical AOP lipid biomarkers, cutting through high-fat backgrounds in liver and brain tissues.

Strict Antioxidant Protocols for Sample Preservation

Toxicologically stressed samples are highly susceptible to rapid ex vivo auto-oxidation. We enforce strict cryogenic quenching and utilize extraction solvents pre-fortified with BHT/EDTA antioxidant shields, ensuring measured oxidative stress reflects true in vivo toxicity.

Absolute Quantification for Regulatory Compliance

Regulatory risk assessments demand irrefutable, reproducible accuracy. We routinely spike >50 stable isotope-labeled (Deuterated/13C) internal standards into our targeted workflows. This strictly controls the analytical Coefficient of Variation (CV) to < 15% across large-scale cohorts.

Selected Case Studies in Mechanistic Toxicology Lipidomics

Selected Publication: Hyötyläinen et al., 2021. Frontiers in Genetics. DOI: 10.3389/fgene.2021.721507

Who needs this: Teams studying PFAS immunotoxicity, endocrine-active pollutants, or exposure-driven metabolic reprogramming in preclinical models.

PFAS-Driven Lipid Remodeling Linked to Early Immune Injury

Method used

Female NOD mice were exposed to perfluoroundecanoic acid (PFUnDA) during gestation, lactation, and early life. Serum samples from offspring were analyzed by comprehensive lipidomics, and the lipid data were evaluated against exposure level, insulitis grade, macrophage counts, and apoptotic markers in pancreatic islets.

Result obtained

PFUnDA exposure produced dose-dependent lipidomic shifts, with reduced phosphatidylcholines, ether phosphatidylcholines, and PUFA-containing triacylglycerols. These lipid changes also tracked with insulitis-related endpoints, making the study a strong example of how mechanistic toxicology lipidomics can connect environmental exposure to pathway-level injury signals rather than phenotype alone.

Recommended path

Bundle A (Untargeted Lipidomics Profiling) → Bundle B (Targeted Validation of phospholipids/sphingolipids) → Bioinformatic correlation analysis

Correlation-based mechanistic toxicology lipidomics figure showing PFAS exposure-associated phospholipid and triglyceride shifts with insulitis-related endpoints.

Spearman correlation between lipid classes and PFUnDA exposure levels

Selected Publication: Li et al., 2022. Frontiers in Pharmacology. DOI: 10.3389/fphar.2022.907271

Who needs this: Toxicologists comparing hepatotoxic mechanisms across chemicals, and teams building liver injury workflows for hazard identification or mechanistic risk assessment.

Chemical-Specific Liver Injury Signatures in Acute Cholestasis Models

Method used

The study established four chemically induced mouse models of acute intrahepatic cholestasis using ANIT, DDC, EE, and LCA. Liver tissues were analyzed by UHPLC-Q-Exactive-MS lipidomics together with GC-MS metabolomics to compare class-level and model-specific disturbance patterns across the cholestatic injury spectrum.

Result obtained

All models showed bile-acid dysregulation, while ceramide and acylcarnitine accumulation suggested mitochondrial dysfunction across groups. The lipidomics layer also separated model-specific phenotypes: ANIT and DDC clustered more closely, whereas EE showed a distinct profile, supporting the value of toxicity mechanism lipid profiling for distinguishing superficially similar liver injury readouts.

Recommended path

Bundle A (Untargeted Lipidomics Profiling) → Bundle B (Targeted ceramide/acylcarnitine validation) → Deep pathway interpretation

Heatmap-based toxicity mechanism lipid profiling figure showing differential hepatic lipid species across chemically induced cholestasis models.

Heatmaps of altered lipid species between acute intrahepatic cholestasis models

Frequently Asked Questions

How does lipidomics facilitate the construction of Adverse Outcome Pathways (AOPs)?

AOPs require a clear, causal link between a Molecular Initiating Event (MIE) and an apical adverse outcome (like reproductive organ failure). Lipidomics acts as the crucial biochemical bridge. By precisely quantifying membrane degradation, signaling shifts, or endocrine precursor depletion, we provide the absolute, quantifiable data needed to validate these mechanistic pathways for regulatory bodies like the EPA and OECD.

What is the difference between adaptive lipid remodeling and a toxicological adverse event?

Biological systems adapt to minor stress by naturally adjusting their lipid composition (e.g., changing membrane saturation). However, a toxicological event triggers irreversible, destructive pathways. We differentiate the two by targeting specific, definitive damage markers—such as heavily oxidized polyunsaturated fatty acids or apoptotic ceramides—that are exclusively generated during actual toxicological injury.

How do you quantify low-abundance inflammatory mediators like eicosanoids in complex liver tissues?

Liver tissues contain overwhelming amounts of triacylglycerols that severely suppress mass spectrometry signals. To quantify trace eicosanoids, we mandate multi-step Solid-Phase Extraction (SPE) enrichment to meticulously strip away the background fat. Combined with highly sensitive LC-MS/MS platforms running in MRM mode, we achieve reliable absolute quantification at pg/mL levels.

Can untargeted lipidomics differentiate between the toxic mechanisms of structurally similar PFAS compounds?

Yes. While different PFAS chain lengths may cause similar phenotypic liver enlargement, their interactions with cellular receptors differ significantly. Untargeted lipidomics provides a holistic metabolic fingerprint. By applying principal component analysis (PCA) and multivariate statistics, we can identify the unique lipid cascades driven by specific PFAS analogs, highlighting subtle mechanistic differences.

How does your platform ensure the stability of oxylipins and prevent ex vivo auto-oxidation?

Oxylipins and other ROS-sensitive lipids degrade rapidly once tissue is harvested. We strictly enforce sub-second liquid nitrogen flash-freezing protocols. During homogenization and extraction, we maintain cryogenic environments and utilize solvent systems pre-loaded with antioxidant shields, ensuring the detected oxidative stress genuinely reflects in vivo toxicity.

Is spatial lipidomics (MALDI-MSI) applicable to whole-body sections of small ecotoxicology models like zebrafish?

Absolutely. MALDI-MSI is highly effective for small aquatic and mammalian models. We can section intact zebrafish, embryos, or bivalves and map the spatial distribution of specific lipids. This allows researchers to visually pinpoint exactly where a lipophilic toxicant bioaccumulates and simultaneously image the localized tissue damage occurring in that specific micro-environment.

How do you handle the data integration of lipidomics with transcriptomics for mechanistic toxicology?

Modern toxicology relies on understanding how gene expression changes ultimately manifest in the metabolome. Through advanced network toxicology algorithms, we mathematically integrate quantitative lipidomic shifts directly with your RNA-Seq data. This direct correlation highlights the specific enzymatic nodes driving the observed toxic lipid phenotype.

What is the sample volume requirement for evaluating endocrine-disrupting effects?

Thanks to the extreme sensitivity of our targeted lipidomics platforms, we require very low sample inputs. Typically, 50 microliters of serum/plasma or 10-30 milligrams of gonadal or liver tissue is completely sufficient to provide comprehensive, absolute quantification of cholesterol and its complex downstream endocrine steroid precursors.

References

Wiklund L, Caccia S, Pípal M, Nymark P, Beronius A. Development of a data-driven approach to Adverse Outcome Pathway network generation: a case study on the EATS-modalities. Frontiers in Toxicology, 2023. https://doi.org/10.3389/ftox.2023.1183824
OECD. Adverse Outcome Pathways. OECD. https://www.oecd.org/en/topics/sub-issues/testing-of-chemicals/adverse-outcome-pathways.html
OECD. Guidance Document for the Use of Adverse Outcome Pathways in Developing Integrated Approaches to Testing and Assessment (IATA). OECD, 2022. https://www.oecd.org/en/publications/guidance-document-for-the-use-of-adverse-outcome-pathways-in-developing-integrated-approaches-to-testing-and-assessment-iata_44bb06c1-en.html
U.S. Environmental Protection Agency. Toxicity Forecasting (ToxCast). U.S. EPA. https://www.epa.gov/comptox-tools/toxicity-forecasting-toxcast
Hyötyläinen T, Fuchs A, Zandona A, et al. Lipidomic Analyses Reveal Modulation of Lipid Metabolism by the PFAS Perfluoroundecanoic Acid (PFUnDA) in Non-Obese Diabetic Mice. Frontiers in Genetics, 2021. https://doi.org/10.3389/fgene.2021.721507
Li W, Chen H, Qian Y, et al. Integrated Lipidomics and Metabolomics Study of Four Chemically Induced Mouse Models of Acute Intrahepatic Cholestasis. Frontiers in Pharmacology, 2022. https://doi.org/10.3389/fphar.2022.907271
Vrijheid M, Fossati S, Maitre L, et al. Multi-omics signatures of the human early life exposome. Nature Communications, 2022. https://doi.org/10.1038/s41467-022-34422-2
Jinot J, Pavličev M. Hallmarks of environmental insults. Cell, 2021. https://doi.org/10.1016/j.cell.2021.01.043

* Our services can only be used for research purposes and Not for clinical use.

Applications:

Online Inquiry

Services

Resource

USA
Tel:
Address:
Email:
Fax:
Germany
Address: